Compass Financial Services Inc Takes $194,000 Position in AbbVie Inc. (NYSE:ABBV)

Compass Financial Services Inc acquired a new position in AbbVie Inc. (NYSE:ABBV) during the fourth quarter, Holdings Channel.com reports. The firm acquired 1,094 shares of the company’s stock, valued at approximately $194,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ABBV. Newbridge Financial Services Group Inc. raised its position in shares of AbbVie by 219.4% during the 4th quarter. Newbridge Financial Services Group Inc. now owns 10,920 shares of the company’s stock worth $1,940,000 after purchasing an additional 7,501 shares during the period. Kestra Private Wealth Services LLC raised its position in shares of AbbVie by 6.3% during the 4th quarter. Kestra Private Wealth Services LLC now owns 148,102 shares of the company’s stock worth $26,318,000 after buying an additional 8,835 shares in the last quarter. Howland Capital Management LLC boosted its stake in AbbVie by 0.4% during the 4th quarter. Howland Capital Management LLC now owns 23,579 shares of the company’s stock valued at $4,190,000 after purchasing an additional 95 shares in the last quarter. Quotient Wealth Partners LLC raised its position in AbbVie by 14.4% in the fourth quarter. Quotient Wealth Partners LLC now owns 7,182 shares of the company’s stock worth $1,276,000 after acquiring an additional 902 shares in the last quarter. Finally, Northeast Investment Management lifted its stake in AbbVie by 1.2% during the fourth quarter. Northeast Investment Management now owns 12,111 shares of the company’s stock valued at $2,152,000 after purchasing an additional 147 shares during the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Price Performance

NYSE ABBV opened at $190.67 on Friday. The firm’s 50-day simple moving average is $177.54 and its two-hundred day simple moving average is $185.60. AbbVie Inc. has a 52 week low of $153.58 and a 52 week high of $207.32. The company has a quick ratio of 0.54, a current ratio of 0.65 and a debt-to-equity ratio of 9.64. The company has a market cap of $336.94 billion, a PE ratio of 79.45, a price-to-earnings-growth ratio of 1.53 and a beta of 0.58.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, January 31st. The company reported $2.16 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.82). AbbVie had a return on equity of 257.91% and a net margin of 7.59%. During the same quarter in the prior year, the business posted $2.79 earnings per share. Research analysts predict that AbbVie Inc. will post 12.32 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on ABBV. Daiwa Capital Markets cut AbbVie from an “outperform” rating to a “neutral” rating and set a $180.00 target price for the company. in a research report on Thursday, December 5th. Bank of America restated a “neutral” rating and issued a $191.00 price objective on shares of AbbVie in a research note on Tuesday, December 10th. BMO Capital Markets lifted their price target on AbbVie from $208.00 to $215.00 and gave the stock an “outperform” rating in a research report on Monday, February 3rd. Piper Sandler Companies reissued an “overweight” rating and set a $220.00 target price on shares of AbbVie in a research report on Tuesday, December 17th. Finally, Citigroup raised their price objective on shares of AbbVie from $205.00 to $215.00 and gave the stock a “buy” rating in a report on Monday, February 3rd. Five analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $208.35.

Insider Buying and Selling

In other news, SVP Kevin K. Buckbee sold 1,800 shares of the firm’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $172.24, for a total transaction of $310,032.00. Following the sale, the senior vice president now owns 6,983 shares of the company’s stock, valued at $1,202,751.92. This trade represents a 20.49 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.25% of the stock is currently owned by insiders.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.